AcelRx gets $20M loan for Phase III work

AcelRx Pharmaceuticals has secured a $20 million loan from Hercules Technology Growth Capital. Earlier this year, the developer attempted to raise $86 million in its IPO, but, like many biotech attempting to raise cash, fell far short of that goal at just $40 million. AcelRx will receive $10 million to start and can draw an additional $10 million before the end of the year. The developer will make interest-only payments for a year, which could continue until September 2012 if certain development goals are met.

"This loan provides AcelRx with the resources to complete our third and last planned Phase III clinical trial for ARX-01," explained CEO Richard King. ARX-01 is a drug/device combo designed to deliver the drug sufentanil to control post-operative pain. "This loan is expected to extend our operating cash runway into the first quarter of 2013."

- here's AcelRx's release

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.